Notícias

I believe that when a stock is down nearly 10% year to date and down 38% over three years, the CEO's job on a quarterly earnings call is not just to report results. It is to rebuild a narrative that investors have lost confidence in. And Novo Nordisk CEO Mike Doustdar is honestly trying that with ...

Lexicon Pharmaceuticals Inc (LXRX) advances its pipeline with strong cash position despite a challenging quarter marked by a net loss and reduced revenues.

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabet

The drugmaker continues to face headwinds.

The real opportunity extends well beyond prescription delivery

Eligible patients can access Wegovy, Zepbound and Foundayo for $50 per month through Amazon Pharmacy.

Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound and Foundayo will be available at a cost of $50 a month.

Novo Nordisk lifts its 2026 outlook as Wegovy pill demand accelerates, even as U.S. pricing, patent losses and competition pressure the second half.

A clinical trial failure and U.S. competition have been tough for the Danish pharmaceutical firm. CFO Karsten Munk says the company is doubling down on innovation and its weight loss pills as it looks towards its next stage of growth.

Reporting 91% growth for Mounjaro, Lilly widened the gap to cardiometabolic rival Novo Nordisk.

Doustdar was fairly fresh off an earnings call, but we connected to discuss a different milestone—his one-year anniversary in the CEO role, which is tomorrow. Introducing culture change had been part of the CEO’s mission since he landed the job, and he arrived with notes, having already worked at Novo Nordisk for 33 years.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State

Key takeawaysEli Lilly’s second-quarter revenue surged 48 per cent to US$22. 97 billion, beating Wall Street expectations by more than US$2 billion.

Novo raised its guidance, but pipeline impairments and slower product development kept investors focused on its competitive position.

📣"I don't know the needs of the two competitors that are right now trying to talk to each other, but we don't see a need for a transformative M&A right now." —Mike Doustdar, CEO of Ozempic maker Novo Nordisk in an interview with the Journal, referring to a recent Financial Times report that AstraZeneca and Bristol Myers Squibb held talks over a tie-up.

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 1.1% and th

BUSINESS The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0429 ET – Novo Nordisk’s second-quarter earnings beat and guidance raise imply minimal changes to the midpoint of consensus estimates, Bernstein analysts write.

Set against the backdrop of a mixed Q2, Novo is eyeing bolt-ons in favour of transformative acquisitions.

LLY crushes Q2 earnings estimates and lifts its 2026 sales outlook as Mounjaro and Zepbound fuel strong revenue growth and newer drugs add momentum.

Amgen beats Q2 earnings and revenue estimates and lifts its 2026 outlook. Key products witness strong growth despite biosimilar pressure on older drugs.

European equities traded in the US as American depositary receipts were edging higher late Wednesday

The Wegovy maker raised its outlook, but investors focused on pricing pressure, a pill sales miss and another pipeline stumble.

After the company reported second quarter earnings and raised its full-year sales guidance, Eli Lilly (LLY) CFO Lucas Montarce outlines the expansion opportunities that the pharmaceutical giant is seeing in its GLP-1 category, specifically the introduction of oral weight-loss drugs to the market.

Novo Nordisk beats Q2 earnings and sales estimates as GLP-1 demand grows, but pricing pressure, outlook concerns and pipeline setbacks sent shares lower.

Novo Nordisk stock has given investors a mixed ride, with solid 1 year gains but a sharp decline over 3 years, even as the broader valuation checks still suggest the shares lean cheap compared with fundamentals. Recent news on blockbuster diabetes and obesity drugs on one side and a failed late stage cardiovascular trial on the other keeps the market focused on what price fairly reflects this balance. Over the past 3 years the share price is down 48.1%, which means long term holders are...

Chief Executive Mike Doustdar’s comments come amid sector focus on M&A and after Novo Nordisk made two disclosures in recent days on its future pipeline that disappointed investors.

<body><p>STORY: :: Novo Nordisk</p><p>'''Right now, the market isn't convinced that Novo Nordisk pipeline of experimental drugs is robust enough to fight against Lilly.''</p><p>:: How is Novo Nordisk future proofing as investors worry about pipeline?</p><p>:: August 5, 2026</p><p>:: Maggie Fick, European Pharma Industry Correspondent&nbsp;</p><p>''The drugmaker on Tuesday raised its full year profit and sales outlook, but investors are less focused on the numbers. They did look at the weaker than expected sales for its new Wegovy pill, and they're more focused on what the answer that the company has is to this question of the expirations of the patents for the company's key drugs. ''</p><p>'''So the name of the game now really is the medicines that Novo Nordisk is testing right now in trials. And also on Tuesday, Novo reported a trial failure for one of its next generation obesity drugs, obesity and diabetes drugs, CagriSema, and we think that's part of the reason that shares fell on these announcements.''</p><p>:: What is CEO Mike Doutsdar's response?</p><p>:: Novo Nordisk</p><p>''So Mike Doustdar acknowledged these recent trials setbacks, but he argued that they don't change the company's strategy. He says the answer is to move faster in research. He's been at the helm of the company now for a year. And he said one of the important steps he took was to combine research and development under one executive, and that that is helping that department move faster with trials. And he continues to say that failures are part of the pharmaceutical industry, that, trials are run with risks and so this is not unusual and they just have to keep moving. He said that it's important for Novo to stick to its strategy of bolt-on acquisitions to complement its own research and development.&nbsp;And he stressed that a transformational acquisition, a big merger, is not something on his agenda and that's for companies that have big problems.''</p></body>

Eli Lilly and Novo Nordisk, the world’s two largest makers of weight-loss and diabetes drugs, raised their full-year forecasts on the back of...

Eli Lilly posted a blockbuster second quarter fueled by continued demand for its portfolio of GLP-1 medications. The world’s biggest drugmaker by market value reported adjusted earnings of $8.38 a share in the period, better than the $6.01 consensus estimate among analysts polled by FactSet. Revenue surged 48% to nearly $23 billion—Wall Street was looking for $20.7 billion.

Investing.com -- CVS Health shares jumped about 5% in premarket trading Wednesday after the company raised its full-year profit guidance following better-than-expected second-quarter results.